These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34969632)

  • 21. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
    Kuboki Y; Terazawa T; Masuishi T; Nakamura M; Watanabe J; Ojima H; Makiyama A; Kotaka M; Hara H; Kagawa Y; Sugimoto N; Kawakami H; Takashima A; Kajiwara T; Oki E; Sunakawa Y; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
    Br J Cancer; 2023 May; 128(10):1897-1905. PubMed ID: 36871043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
    Martínez-Lago N; Chucla TC; De Castro BA; Ponte RV; Rendo CR; Rodriguez MIG; Diaz SS; Suarez BG; de la Cámara Gomez J; Fernández FB; Salvador MM; Lopez MR
    Sci Rep; 2022 Aug; 12(1):14612. PubMed ID: 36028552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
    BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
    Sunakawa Y; Kuboki Y; Watanabe J; Terazawa T; Kawakami H; Yokota M; Nakamura M; Kotaka M; Sugimoto N; Ojima H; Oki E; Kajiwara T; Yamamoto Y; Tsuji Y; Denda T; Tamura T; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
    Target Oncol; 2024 Jan; 19(1):59-69. PubMed ID: 38194163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
    Matsuoka S; Fujii H; Iihara H; Ohata K; Hirose C; Watanabe D; Sadaka S; Kiyama S; Makiyama A; Takahashi T; Kobayashi R; Matsuhashi N; Suzuki A
    Anticancer Res; 2023 May; 43(5):2351-2357. PubMed ID: 37097664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
    Prager GW; Taieb J; Fakih M; Ciardiello F; Van Cutsem E; Elez E; Cruz FM; Wyrwicz L; Stroyakovskiy D; Pápai Z; Poureau PG; Liposits G; Cremolini C; Bondarenko I; Modest DP; Benhadji KA; Amellal N; Leger C; Vidot L; Tabernero J;
    N Engl J Med; 2023 May; 388(18):1657-1667. PubMed ID: 37133585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
    Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E
    Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
    Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
    Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
    Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E
    Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
    Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
    Lin YL; Liu KL; Lin BR
    Medicine (Baltimore); 2020 Oct; 99(43):e22780. PubMed ID: 33120790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis.
    Prejac J; Omrčen T; Radić J; Vrdoljak E; Fröbe A; Pleština S
    Oncology; 2024; 102(3):217-227. PubMed ID: 37699377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
    Sousa MJ; Gomes I; Pereira TC; Magalhães J; Basto R; Paulo J; Jacinto P; Bonito N; Sousa G
    Cancer Treat Res Commun; 2022; 31():100531. PubMed ID: 35172243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1376-1387. PubMed ID: 32653227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
    Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [
    Kim SY; Jung JH; Lee HJ; Soh H; Lee SJ; Oh SJ; Chae SY; Lee JH; Lee SJ; Hong YS; Kim TW; Moon DH
    Cancer Res; 2017 Dec; 77(24):7120-7130. PubMed ID: 29055019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
    Maeda F; Gan S; Yamada A; Kajiyama D; Tokitou F; Kawaguchi M; Amagasa H; Motoyama K; Ganno H; Imai K; Ami K; Iida S; Fukuda A; Ando M; Okano Y
    Gan To Kagaku Ryoho; 2021 Mar; 48(3):419-421. PubMed ID: 33790174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.